Authors: Panaccione, R Fedorak, RN Feagan, B Steinhart, H Wild, G Baron, D Bernstein, C Bitton, A Buckley, A Croitoru, K Enns, R Greenberg, G Hassard, P Semlacher, E Sutherland, L Tavenor, A Tourigny, M Walli, E Williams, N

Citation: R. Panaccione et al., Canadian Association of Gastroenterology clinical practice guidelines: Theuse of infliximab in Crohn's disease, CAN J GASTR, 15(6), 2001, pp. 367-370

Authors: Schreiber, S Campieri, M Colombel, JF van Deventer, SJH Feagan, B Fedorak, R Forbes, A Gassull, M Gendre, JP van Hogezand, RA Lofberg, R Modigliani, R Pallone, F Petritsch, W Prantera, C Rampton, D Seibold, F Vatn, M Zeitz, M Rutgeerts, P

Citation: S. Schreiber et al., Use of anti-tumour necrosis factor agents in inflammatory bowel disease - European guidelines for 2001-2003, INT J COL R, 16(1), 2001, pp. 1-11

Authors: Fedorak, RN Gangl, A Elson, CO Rutgeerts, P Schreiber, S Wild, G Hanauer, SB Kilian, A Cohard, M LeBeaut, A Feagan, B

Citation: Rn. Fedorak et al., Recombinant human interleukin 10 in the treatment of patients with mild tomoderately active Crohn's disease, GASTROENTY, 119(6), 2000, pp. 1473-1482